Cardiff Oncology, Inc.
CRDF· Nasdaq
CRDFCardiff Oncology, Inc.
Filed Aug 14, 2013 · 10-Q · 45 days after period end · 0001104659-13-063996
| Metric | Q2 2013 | Q2 2012 | Q2 2011 |
|---|---|---|---|
| Revenue | $49.00K | $42.00K | $79.86K |
| Net Income | -$5.27M | -$3.43M | -$449.16K |
| EPS Diluted | -$0.34 | -$0.28 | -$0.05 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cardiff Oncology, Inc. · CIK 1213037 · Engraved from SEC EDGAR
ended Jun 30, 2013 · filed Aug 14, 2013 · 45 d after period end
